Host OTUB2 and viral PLpro stabilize NSP8 to promote SARS-CoV-2 replication Authors: Wenying Gao, Hongfei Wang, Jingguo Xin, Chenjia Gu, Lu Qiu, Xue Zhang, Chunlei Wang, Qingxiang Zhang, Shuai Li, Guangquan Li, Wenyan Zhang Published: 2026 ABSTRACT The ubiquitin-proteasome system (UPS) plays a central role in antiviral defense but is also frequently hijacked by viruses to facilitate their replication. Here, we demonstrate that the host deubiquitinase OTUB2 stabilizes the viral replication factor NSP8 of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through a dual-track mechanism. OTUB2 directly removes polyubiquitin chains from NSP8 to prevent its degradation. In parallel, OTUB2 stabilizes the viral papain-like protease (PLpro), which further promotes NSP8 stability through deubiquitination. Together, these effects preserve the functional integrity of the viral replication-transcription complex. Mechanistically, OTUB2-mediated stabilization of NSP8 potentiates NSP8-dependent suppression of type I interferon signaling, thereby promoting viral replication and immune evasion. Importantly, inhibition of OTUB2 disrupts OTUB2-mediated stabilization of NSP8 and PLpro, resulting in a marked reduction in viral replication and disease severity in cell culture systems and a hamster infection model. Collectively, our findings reveal a previously unrecognized mechanism by which SARS-CoV-2 utilizes the host deubiquitination system to stabilize its replication machinery and identify OTUB2 as a potential target for host-directed antiviral intervention. Introduction The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, has resulted in a global health crisis of unprecedented scale (Chen et al., 2025; Holmes et al., 2021). Elucidating its molecular pathogenesis and defining critical host-virus interactions are essential for developing effective antiviral strategies. Among the structural, nonstructural, and accessory proteins encoded by SARS-CoV-2, nonstructural protein 8 (NSP8) serves as a core component of the viral replication machinery by forming a complex with NSP7 and NSP12 to enhance the activity of the RNA-dependent RNA polymerase (RdRp) (Bai et al., 2022; Yang and Rao, 2021). Beyond its role in viral RNA synthesis, NSP8 also interacts with host cellular pathways and actively suppresses the type I interferon (IFN-I) signaling, thereby contributing to immune evasion and enhanced viral infectivity (Zhang et al., 2023). Post-translational modifications (PTMs), particularly ubiquitination, play critical roles in regulating protein stability, trafficking, and immune signaling (Hsieh et al., 2026; Xiao et al., 2025). During SARS-CoV-2 infection, numerous viral and host proteins involved in replication and immune defense undergo dynamic ubiquitination, underscoring the importance of deubiquitinases (DUBs) in viral pathogenesis. Notably, SARS-CoV-2 encodes its own viral deubiquitinase, papain-like protease (PLpro), which processes viral polyproteins while antagonizing host immunity by removing ubiquitin and ISG15 from key signaling molecules, including interferon regulatory factor 3, thereby suppressing IFN-I responses (Moustaqil et al., 2021; Shin et al., 2020; Ton et al., 2022; Wydorski et al., 2023). Emerging evidence further indicates that beyond encoding its own DUB, SARS-CoV-2 also exploits host deubiquitinases to stabilize viral proteins. For instance, the host deubiquitinase USP29 preserves ORF9b stability by preventing its ubiquitin-mediated degradation, and USP13 similarly stabilizes NSP13 to promote viral replication (Gao et al., 2022; Guo et al., 2021). Within this broader PTM framework, the viral replication factor NSP8 undergoes both ubiquitination and ISGylation, and its ISGylation can be reversed by PLpro (Hou et al., 2025). In contrast, the host mechanisms governing NSP8 ubiquitination remain undefined. This gap directs attention to host deubiquitinases that may regulate viral protein stability. Among these, OTUB2, a member of the ovarian tumor domain-containing (OTU) family, has been linked to protein stability and immune signaling (Zhu et al., 2021). Although studied primarily in cancer-related contexts, its role in viral infection is less well defined. Structural and functional analyses indicate that OTUB2 shares catalytic features with PLpro, particularly in cysteine protease activity and ubiquitin chain processing (Sivakumar and Stein, 2021), suggesting a potential role in PTM-dependent regulation of viral proteins. Whether OTUB2 directly engages SARS-CoV-2 replication factors or contributes to the stability of viral immune evasion components remains unresolved. In this study, we combined biochemical and virological approaches to demonstrate that OTUB2 regulates viral protein stability and viral replication, highlighting its potential as a host-directed antiviral target. Results OTUB2 expression level is positively correlated with SARS-CoV-2 infection To assess whether OTUB2 expression is associated with COVID-19 disease, we compared the mRNA levels of OTUB2 in healthy individuals and SARS-CoV-2 infected patients and found that the OTUB2 mRNA levels were markedly higher in patients than in healthy controls (Fig. 1A and B). To confirm the association of OTUB2 expression and SARS-CoV-2 infection, we measured the endogenous mRNA levels of OTUB2 when Caco-2 and Vero cells were infected with the SARS-CoV-2 XBB variant. As expected, SARS-CoV-2 infection induced a significant upregulation of OTUB2 expression (Fig. 1C and D). To examine whether OTUB2 affects SARS-CoV-2 infectivity, we overexpressed OTUB2 in Caco-2 or Vero cells, followed by infection with the XBB variant. The results showed that OTUB2 enhanced SARS-CoV-2 replication, as indicated by increased viral RNA levels in the supernatants and elevated intracellular N protein levels. (Fig. 1E and F).Fig. 1OTUB2 is highly expressed in SARS-CoV-2 patients and promotes SARS-CoV-2 replication. A, B OTUB2 is highly expressed in SARS-CoV-2 patients. A total of 98 blood samples, including those from healthy individuals and COVID-19 patients, were collected. PBMCs were isolated, and RNA is extracted using the TRIzol method. RT-qPCR was performed for detection. C, D OTUB2 mRNA levels are significantly increased in cell lines after SARS-CoV-2 infection. Caco-2 and Vero cells were infected with SARS-CoV-2 XBB (MOI = 0.01). The medium was replaced 2 h post-infection, and cells were harvested at the indicated time points. Intracellular OTUB2 mRNA levels were measured by RT-qPCR. E, F OTUB2 promotes SARS-CoV-2 replication. OTUB2 was transfected into Caco-2, Vero cells, and samples were collected 48 h post-infection for RT-qPCR and Western blot analyses. Data are representative of three independent experiments and presented as the mean ± SD (n = 3). Significance is determined using a t-test: ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗, P < 0.001; ∗∗∗∗, P < 0.0001. OTUB2 is highly expressed in SARS-CoV-2 patients and promotes SARS-CoV-2 replication. A, B OTUB2 is highly expressed in SARS-CoV-2 patients. A total of 98 blood samples, including those from healthy individuals and COVID-19 patients, were collected. PBMCs were isolated, and RNA is extracted using the TRIzol method. RT-qPCR was performed for detection. C, D OTUB2 mRNA levels are significantly increased in cell lines after SARS-CoV-2 infection. Caco-2 and Vero cells were infected with SARS-CoV-2 XBB (MOI = 0.01). The medium was replaced 2 h post-infection, and cells were harvested at the indicated time points. Intracellular OTUB2 mRNA levels were measured by RT-qPCR. E, F OTUB2 promotes SARS-CoV-2 replication. OTUB2 was transfected into Caco-2, Vero cells, and samples were collected 48 h post-infection for RT-qPCR and Western blot analyses. Data are representative of three independent experiments and presented as the mean ± SD (n = 3). Significance is determined using a t-test: ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗, P < 0.001; ∗∗∗∗, P < 0.0001. OTUB2 stabilizes NSP8 Since OTUB2 enhances SARS-CoV-2 infectivity, we next investigate the underlying mechanism how OTUB2 affects the progression of SARS-CoV-2 infection. Given that OTUB2 is a deubiquitinating enzyme, we first examined its effect on the stability of SARS-CoV-2-encoded proteins. The results showed that OTUB2 increased the stability of NSP8, ORF6 and PLpro (Supplementary Fig. S1). Since deubiquitinases that regulate ORF6 stability have already been reported, we focused our subsequent investigation on NSP8 and PLpro. First, we validated that OTUB2 stabilizes NSP8. We further confirmed that NSP8 was stabilized by proteasome inhibitors and underwent ubiquitination (Fig. 2A and B), which is consistent with the previous report (Fan et al., 2024). To determine whether OTUB2 is the primary regulator of NSP8 stability, we next screened members of the OTU family and other deubiquitinase family members and found that only OTUB2 effectively stabilized NSP8 (Fig. 2C). Moreover, OTUB2 increased NSP8 protein levels in a dose-dependent manner (Fig. 2D). Additionally, cycloheximide (CHX) chase assays demonstrated that OTUB2 markedly extended the half-life of NSP8 (Fig. 2E). Conversely, treatment with an OTUB2 inhibitor (OTUB2-IN) (Ren et al., 2024) abolished the OTUB2-mediated stabilization of NSP8 (Fig. 2F). Collectively, these findings identify OTUB2 as a key regulator of NSP8 stability.Fig. 2OTUB2 stabilizes NSP8 expression. A Proteasome inhibitors stabilize NSP8 expression. HEK293T cells were transfected with NSP8 and treated with 5 μM MG132, 10 μM Bortezomib, 10 μM BafiloMycin A1, 10 μM Vinblastine or DMSO for 12 h prior to harvest. Protein expression was analyzed by Western blotting (WB). B NSP8 is ubiquitinated. HEK293T cells were co-transfected with Ub-HA and NSP8-Myc and treated with 5 μM MG132 for 12 h before harvest. Co-IP with anti-Myc and WB analysis were performed. C OTUB2 stabilizes NSP8. Different deubiquitinating enzymes were co-transfected with NSP8 into HEK293T cells, and samples were collected 48 h post-transfection for WB analysis. D OTUB2 stabilizes NSP8 in a dose-dependent manner. E OTUB2 expression prolongs the half-life of NSP8. Empty vector or OTUB2 was co-transfected with NSP8 into HEK293T cells. At 24 h post-transfection, cells were treated with 50 μg/mL cycloheximide (CHX) and harvested at the indicated time points. Protein levels were determined by WB, and NSP8 expression was quantified using ImageJ and normalized to actin. F OTUB2-IN inhibits OTUB2-dependent stabilization of NSP8. Cells were treated with OTUB2-IN at the indicated concentrations for 12 h prior to sample collection. Protein levels were determined by WB. Statistical significance was determined by one-way ANOVA: ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001. OTUB2 stabilizes NSP8 expression. A Proteasome inhibitors stabilize NSP8 expression. HEK293T cells were transfected with NSP8 and treated with 5 μM MG132, 10 μM Bortezomib, 10 μM BafiloMycin A1, 10 μM Vinblastine or DMSO for 12 h prior to harvest. Protein expression was analyzed by Western blotting (WB). B NSP8 is ubiquitinated. HEK293T cells were co-transfected with Ub-HA and NSP8-Myc and treated with 5 μM MG132 for 12 h before harvest. Co-IP with anti-Myc and WB analysis were performed. C OTUB2 stabilizes NSP8. Different deubiquitinating enzymes were co-transfected with NSP8 into HEK293T cells, and samples were collected 48 h post-transfection for WB analysis. D OTUB2 stabilizes NSP8 in a dose-dependent manner. E OTUB2 expression prolongs the half-life of NSP8. Empty vector or OTUB2 was co-transfected with NSP8 into HEK293T cells. At 24 h post-transfection, cells were treated with 50 μg/mL cycloheximide (CHX) and harvested at the indicated time points. Protein levels were determined by WB, and NSP8 expression was quantified using ImageJ and normalized to actin. F OTUB2-IN inhibits OTUB2-dependent stabilization of NSP8. Cells were treated with OTUB2-IN at the indicated concentrations for 12 h prior to sample collection. Protein levels were determined by WB. Statistical significance was determined by one-way ANOVA: ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001. OTUB2 interacts with NSP8 and removes polyubiquitination of NSP8 To elucidate how OTUB2 stabilizes NSP8, we performed co-immunoprecipitation (Co-IP) assay to determine whether OTUB2 interacts with NSP8. Co-IP assays revealed an interaction between NSP8 and OTUB2 (Fig. 3A and B). Immunofluorescence co-localization analysis showed that OTUB2 and NSP8 were mainly co-localized in the cytoplasm (Fig. 3C). OTUB2 is a 234-amino acid protein containing 10 α-helices and 4 β-sheets. Based on its domain structure, we generated N- and C-terminal truncation constructs (Supplementary Fig. S2A). Co-IP analysis showed that the 51–234 aa region of OTUB2 mediated its interaction with NSP8 (Supplementary Fig. S2B), consistent with AlphaFold prediction, which identified residues 146R, 148D, 155D, 156E, 176D, 181T, 210E, and 220Y as potential hydrogen bond-forming sites (Supplementary Fig. S2C).Fig. 3OTUB2 interacts with NSP8 and deubiquitinates it. A, B Co-IP assays were performed to analyze the interaction between OTUB2 and NSP8. C Subcellular localization of NSP8 and OTUB2 was analyzed by confocal microscopy. Scale bar: 10 μm. D OTUB2 deubiquitinated NSP8. HEK293T cells were transfected with indicated plasmids and treated with 5 μM MG132 for 12 h prior to harvest. Co-IP (Co-IP with anti-Flag) and Western blot (WB) analyses were performed. E Knockdown of OTUB2 reduced NSP8 deubiquitination. NSP8 ubiquitination in OTUB2-silenced and control cells was analyzed by Co-IP (with anti-Flag), followed by WB. F OTUB2-mediated deubiquitination of NSP8 was also assessed with purified proteins. HEK293T cells were co-transfected with Ub-HA and NSP8-Flag expression plasmids. Ubiquitinated NSP8 was subsequently purified from cell lysates using anti-Flag antibody-conjugated Protein G agarose beads. OTUB2-Myc was purified by anti-Myc antibody-conjugated Protein G agarose beads. Ubiquitinated NSP8-Flag was incubated with OTUB2-Myc for 1 h at 37 °C, followed by WB analysis. G Confirmation of OTUB2 knockout in HEK293T cells by WB. H The catalytically inactive OTUB2 mutant fails to stabilize NSP8 expression. HEK293T cells were transfected with NSP8-Flag together with OTUB2-Myc WT or the mutants, and cells were harvested 48 h post-transfection for WB analysis of NSP8 protein levels. I Co-IP analysis shows that the OTUB2 C51A mutant loses the ability to deubiquitinate NSP8. LIn vitro deubiquitination assay with purified proteins demonstrate that the catalytically inactive OTUB2 mutant is unable to remove ubiquitin from NSP8. The experiment was performed as described in Fig. 3F. Statistical significance was determined by one-way ANOVA: ∗∗∗∗P < 0.0001. OTUB2 interacts with NSP8 and deubiquitinates it. A, B Co-IP assays were performed to analyze the interaction between OTUB2 and NSP8. C Subcellular localization of NSP8 and OTUB2 was analyzed by confocal microscopy. Scale bar: 10 μm. D OTUB2 deubiquitinated NSP8. HEK293T cells were transfected with indicated plasmids and treated with 5 μM MG132 for 12 h prior to harvest. Co-IP (Co-IP with anti-Flag) and Western blot (WB) analyses were performed. E Knockdown of OTUB2 reduced NSP8 deubiquitination. NSP8 ubiquitination in OTUB2-silenced and control cells was analyzed by Co-IP (with anti-Flag), followed by WB. F OTUB2-mediated deubiquitination of NSP8 was also assessed with purified proteins. HEK293T cells were co-transfected with Ub-HA and NSP8-Flag expression plasmids. Ubiquitinated NSP8 was subsequently purified from cell lysates using anti-Flag antibody-conjugated Protein G agarose beads. OTUB2-Myc was purified by anti-Myc antibody-conjugated Protein G agarose beads. Ubiquitinated NSP8-Flag was incubated with OTUB2-Myc for 1 h at 37 °C, followed by WB analysis. G Confirmation of OTUB2 knockout in HEK293T cells by WB. H The catalytically inactive OTUB2 mutant fails to stabilize NSP8 expression. HEK293T cells were transfected with NSP8-Flag together with OTUB2-Myc WT or the mutants, and cells were harvested 48 h post-transfection for WB analysis of NSP8 protein levels. I Co-IP analysis shows that the OTUB2 C51A mutant loses the ability to deubiquitinate NSP8. LIn vitro deubiquitination assay with purified proteins demonstrate that the catalytically inactive OTUB2 mutant is unable to remove ubiquitin from NSP8. The experiment was performed as described in Fig. 3F. Statistical significance was determined by one-way ANOVA: ∗∗∗∗P < 0.0001. We then assessed whether OTUB2 affects NSP8 ubiquitination. Cell-based deubiquitination assays showed that overexpression of OTUB2 removed the ubiquitination of NSP8 (Fig. 3D), while OTUB2 knockdown increased NSP8 ubiquitination (Fig. 3E). Consistently, in vitro deubiquitination assays with purified proteins further demonstrated that OTUB2 directly removed ubiquitination of NSP8 (Fig. 3F). To determine if the catalytic activity of OTUB2 is necessary for NSP8 stabilization, we generated deubiquitinase-deficient mutants of OTUB2 (Supplementary Fig. S2A) and established OTUB2-knockout HEK293T cells (Supplementary Fig. S2D). Successful OTUB2 knockout was confirmed by DNA sequencing and immunoblotting (Fig. 3G, Supplementary Fig. S2E). The OTUB2 C51A mutant failed to stabilize NSP8 in OTUB2-knockout HEK293T cells (Fig. 3H), confirming that the catalytic residue C51 is essential for NSP8 regulation. This finding is consistent with previous studies (Mei et al., 2025). Further, deubiquitination assays showed that the C51A mutant completely lost its ability to remove ubiquitin from NSP8 compared with the wild-type protein (Fig. 3I). In vitro deubiquitination analysis with purified proteins further confirmed that the catalytically inactive OTUB2 mutant could not cleave ubiquitin from NSP8 (Fig. 3L). Collectively, these results demonstrate that OTUB2 specifically interacts with and stabilizes NSP8 in deubiquitinase activity dependent manner. OTUB2 stabilizes PLpro In addition to stabilizing NSP8, OTUB2 also regulates the stability of other viral proteins, including PLpro. As shown in Supplementary Fig. S1, OTUB2 increased PLpro protein levels, prompting further investigation into its stability. To determine whether PLpro undergoes proteasomal degradation, cells were treated with proteasome inhibitors MG132 and Bortezomib, both of which increased PLpro protein levels. However, treatment with the lysosomal inhibitors Bafilomycin A1 or the autophagosome inhibitor vinblastine had no apparent effect on PLpro levels (Fig. 4A). Co-IP analysis confirmed that PLpro underwent ubiquitination (Fig. 4B). Furthermore, the CHX assay showed that OTUB2 extended the half-life of PLpro protein (Fig. 4C), indicating that OTUB2 stabilizes PLpro. This stabilizing effect was abolished by treatment with an OTUB2 inhibitor (Fig. 4D). The catalytic inactive OTUB2 C51A mutant also failed to stabilize PLpro compared to the wild-type OTUB2 (Fig. 4E). To examine whether OTUB2 interacts with PLpro, Co-IP assays revealed an interaction between OTUB2 and PLpro (Fig. 4F). Additionally, AlphaFold modeling predicted seven hydrogen bonds between OTUB2 (cyan) and PLpro (blue), supporting interaction between the two proteins (Fig. 4G). Finally, deubiquitination assays showed that OTUB2 removes polyubiquitin chains from PLpro (Fig. 4H). Together, these results indicate that OTUB2 interacts with PLpro and stabilizes it by deubiquitinating and preventing its proteasomal degradation.Fig. 4OTUB2 stabilizes PLpro expression. A PLpro stability is regulated by proteasome inhibition. B Ubiquitination of PLpro was confirmed by Co-IP analysis. C OTUB2 expression prolongs the half-life of the PLpro protein. HEK293T cells were transfected with OTUB2-Myc and PLpro-Flag for 4 h, then treated with 50 μg/mL cycloheximide (CHX) and harvested at the indicated time points. Protein levels were analyzed by immunoblotting, and PLpro expression was quantified using ImageJ normalized to actin. D OTUB2-IN inhibits the ability of OTUB2 to stabilize PLpro expression. E The catalytically inactive OTUB2 mutant (C51A) fails to stabilize PLpro expression. F Co-IP analysis confirms the interaction between OTUB2 and PLpro. G AlphaFold-predicted structural model of the OTUB2-PLpro interaction, with OTUB2 shown in cyan and PLpro in blue. H OTUB2 deubiquitinates PLpro. HEK293T cells were transfected with Ub-Flag, OTUB2-Myc, and PLpro-HA. Cells were treated with 5 μM MG132 for 12 h before harvest. Cell lysates were Co-IP with anti-HA antibody-conjugated agarose beads, and both input and Co-IP samples were analyzed by Western blot analysis. OTUB2 stabilizes PLpro expression. A PLpro stability is regulated by proteasome inhibition. B Ubiquitination of PLpro was confirmed by Co-IP analysis. C OTUB2 expression prolongs the half-life of the PLpro protein. HEK293T cells were transfected with OTUB2-Myc and PLpro-Flag for 4 h, then treated with 50 μg/mL cycloheximide (CHX) and harvested at the indicated time points. Protein levels were analyzed by immunoblotting, and PLpro expression was quantified using ImageJ normalized to actin. D OTUB2-IN inhibits the ability of OTUB2 to stabilize PLpro expression. E The catalytically inactive OTUB2 mutant (C51A) fails to stabilize PLpro expression. F Co-IP analysis confirms the interaction between OTUB2 and PLpro. G AlphaFold-predicted structural model of the OTUB2-PLpro interaction, with OTUB2 shown in cyan and PLpro in blue. H OTUB2 deubiquitinates PLpro. HEK293T cells were transfected with Ub-Flag, OTUB2-Myc, and PLpro-HA. Cells were treated with 5 μM MG132 for 12 h before harvest. Cell lysates were Co-IP with anti-HA antibody-conjugated agarose beads, and both input and Co-IP samples were analyzed by Western blot analysis. The deubiquitinase PLpro encoded by SARS-CoV-2 stabilizes NSP8 by removing its ubiquitination Previous studies have shown that the protease PLpro encoded by SARS-CoV-2 shares a structurally similar catalytic center to OTUB2 (Fig. 5A and B) (Sivakumar and Stein, 2021). We then examined the effect of PLpro on NSP8 stability. The results showed that PLpro enhanced NSP8 stability in a dose-dependent manner (Fig. 5C). Additionally, CHX chase assays further confirmed that PLpro extended the half-life of NSP8 (Fig. 5D). Conversely, treatment with a PLpro inhibitor abolished PLpro’s stabilizing effect on NSP8 (Fig. 5E). Co-IP analysis confirmed an interaction between PLpro and NSP8 (Fig. 5F), and immunofluorescence co-localization assay showed that PLpro and NSP8 co-localized in the cytoplasm (Fig. 5G). Similar to OTUB2, PLpro can directly deubiquitinate NSP8 (Fig. 5H). These results confirm that PLpro stabilizes NSP8 by removing its ubiquitination.Fig. 5PLpro stabilizes NSP8 expression. A, B Active sites of the deubiquitinase domains of SARS-CoV-2 PLpro and OTUB2 are shown. The catalytic centers are composed of Cys-His-Asp/Asn residues. C PLpro stabilizes NSP8 expression in a dose-dependent manner. D PLpro prolongs the half-life of NSP8. HEK293T cells were transfected as indicated, 24 h post-transfection, treated with 50 μg/mL CHX. Cells were harvested at the indicated time points, and protein levels were analyzed by Western blot (WB) analysis. NSP8 expression was quantified using ImageJ and normalized to actin. E PLpro inhibitor suppresses PLpro-mediated stabilization of NSP8. Cells were treated with the inhibitor at the indicated concentrations for 12 h prior to cell collection, protein levels were analyzed by WB. F PLpro interacts with NSP8. G Subcellular localization of NSP8 and PLpro was analyzed by confocal microscopy. Scale bar: 10 μm. H PLpro deubiquitinates NSP8. HEK293T cells were transfected as indicated and treated with 5 μM MG132 for 12 h before harvest. Cell lysates were Co-IP with anti-Myc, followed by WB. Statistical significance was determined by one-way ANOVA: ∗∗∗P < 0.001. PLpro stabilizes NSP8 expression. A, B Active sites of the deubiquitinase domains of SARS-CoV-2 PLpro and OTUB2 are shown. The catalytic centers are composed of Cys-His-Asp/Asn residues. C PLpro stabilizes NSP8 expression in a dose-dependent manner. D PLpro prolongs the half-life of NSP8. HEK293T cells were transfected as indicated, 24 h post-transfection, treated with 50 μg/mL CHX. Cells were harvested at the indicated time points, and protein levels were analyzed by Western blot (WB) analysis. NSP8 expression was quantified using ImageJ and normalized to actin. E PLpro inhibitor suppresses PLpro-mediated stabilization of NSP8. Cells were treated with the inhibitor at the indicated concentrations for 12 h prior to cell collection, protein levels were analyzed by WB. F PLpro interacts with NSP8. G Subcellular localization of NSP8 and PLpro was analyzed by confocal microscopy. Scale bar: 10 μm. H PLpro deubiquitinates NSP8. HEK293T cells were transfected as indicated and treated with 5 μM MG132 for 12 h before harvest. Cell lysates were Co-IP with anti-Myc, followed by WB. Statistical significance was determined by one-way ANOVA: ∗∗∗P < 0.001. OTUB2 acts in parallel with PLpro to stabilize NSP8 Both OTUB2 and PLpro stabilize NSP8 through removing the ubiquitination of NSP8 and preventing its degradation. To examine whether these two deubiquitinases act cooperatively, OTUB2-knockout HEK293T cells were transfected with OTUB2 and PLpro either individually or in combination. The results showed that both PLpro and OTUB2 could independently stabilize NSP8. OTUB2 exhibited a stronger stabilizing effect than PLpro, while co-expression of PLpro and OTUB2 resulted in the highest NSP8 level (Fig. 6A), which was further supported by a CHX stability assay (Fig. 6B). Treatment with an OTUB2 inhibitor offset the ability of PLpro alone to stabilize NSP8 (Fig. 6C lane 3). Consistently, the OTUB2 inhibitor impaired NSP8 stabilization mediated either by OTUB2 alone or by the combined expression of OTUB2 and PLpro (Fig. 6C). Further Co-IP experiments showed that NSP8 interacted with PLpro and OTUB2 individually (Fig. 6D lane 2 and lane 3), and also simultaneously interacted with PLpro and OTUB2 when PLpro and OTUB2 were co-expressed with NSP8 (Fig. 6D lane 4). In OTUB2-knockout HEK293T cells, deubiquitination assays showed that co-expression of OTUB2 and PLpro led to more efficient removal of ubiquitin from NSP8 than either protein alone (Fig. 6E). Together, these results indicate that OTUB2 and PLpro cooperatively stabilize NSP8 through coordinated deubiquitination.Fig. 6OTUB2 cooperates with PLpro to stabilize NSP8 expression. A OTUB2 and PLpro cooperatively stabilize NSP8 expression. HEK293T OTUB2-KO cells were transfected with NSP8-Flag, OTUB2-Myc, and PLpro-Flag as indicated. Cells were harvested 48 h post-transfection and subjected to Western blot (WB) analysis. NSP8 protein levels were quantified using ImageJ and normalized to actin. B Co-expression of OTUB2 and PLpro prolongs the half-life of NSP8. HEK293T cells were transfected with NSP8-Flag, OTUB2-Myc, and PLpro-Flag. At 24 h post-transfection, cells were treated with 50 μg/mL CHX and harvested at the indicated time points. Protein levels were determined by WB, and NSP8 expression was quantified using ImageJ and normalized to actin. C OTUB2-IN suppresses the cooperative effect of OTUB2 and PLpro on NSP8 stabilization. HEK293T cells were transfected with NSP8-Flag, OTUB2-Myc, and PLpro-Flag and treated with the inhibitor for 12 h prior to sample collection. NSP8 protein levels were analyzed by WB, quantified using ImageJ, and normalized to actin. D Co-IP analysis of the interactions among NSP8, OTUB2, and PLpro. E OTUB2 and PLpro cooperatively deubiquitinate NSP8. HEK293T OTUB2-KO cells were transfected with Ub-HA, NSP8-Myc, OTUB2-V5, and PLpro-Flag and treated with 5 μM MG132 for 12 h prior to harvest. Cell lysates were Co-IP using Myc antibody–conjugated agarose beads, than proteins were analyzed by WB. Statistical significance was determined by one-way ANOVA: ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001. OTUB2 cooperates with PLpro to stabilize NSP8 expression. A OTUB2 and PLpro cooperatively stabilize NSP8 expression. HEK293T OTUB2-KO cells were transfected with NSP8-Flag, OTUB2-Myc, and PLpro-Flag as indicated. Cells were harvested 48 h post-transfection and subjected to Western blot (WB) analysis. NSP8 protein levels were quantified using ImageJ and normalized to actin. B Co-expression of OTUB2 and PLpro prolongs the half-life of NSP8. HEK293T cells were transfected with NSP8-Flag, OTUB2-Myc, and PLpro-Flag. At 24 h post-transfection, cells were treated with 50 μg/mL CHX and harvested at the indicated time points. Protein levels were determined by WB, and NSP8 expression was quantified using ImageJ and normalized to actin. C OTUB2-IN suppresses the cooperative effect of OTUB2 and PLpro on NSP8 stabilization. HEK293T cells were transfected with NSP8-Flag, OTUB2-Myc, and PLpro-Flag and treated with the inhibitor for 12 h prior to sample collection. NSP8 protein levels were analyzed by WB, quantified using ImageJ, and normalized to actin. D Co-IP analysis of the interactions among NSP8, OTUB2, and PLpro. E OTUB2 and PLpro cooperatively deubiquitinate NSP8. HEK293T OTUB2-KO cells were transfected with Ub-HA, NSP8-Myc, OTUB2-V5, and PLpro-Flag and treated with 5 μM MG132 for 12 h prior to harvest. Cell lysates were Co-IP using Myc antibody–conjugated agarose beads, than proteins were analyzed by WB. Statistical significance was determined by one-way ANOVA: ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001. OTUB2 enhances SARS-CoV-2 infectivity through stabilizing NSP8 Previous studies have shown that NSP8 acts as a negative regulator of IFN-I signaling by inhibiting IFN-β production and NF-κB pathway activation (Zhang et al., 2023). Thus, we next investigated whether OTUB2 affects NSP8-mediated suppression of IFN-β signaling. The results showed that OTUB2 overexpression increased NSP8 levels, thereby enhancing NSP8-mediated inhibition IFN-β reporter activity activated by retinoic-acid inducible gene I (RIG-I) or mitochondrial antiviral signaling protein (MAVS) respectively (Fig. 7A and B). In contrast, treatment with an OTUB2 inhibitor prevented OTUB2 from enhancing NSP8-mediated inhibition of IFN-β signaling (Fig. 7C). We further assessed whether OTUB2 stabilizes NSP8 to enhance its suppression of NF-κB activation. The results showed that OTUB2 overexpression increased NSP8 protein levels, resulting in enhanced inhibition of NF-κB luciferase reporter activity (Supplementary Fig. S3A and B). This effect was reversed by treatment with an OTUB2-specific inhibitor, supporting a role of OTUB2 in regulating NSP8 stability and function (Supplementary Fig. S3C).Fig. 7OTUB2 increases SARS-CoV-2 infectivity through stabilizing NSP8. A, B OTUB2 promotes NSP8 inhibition on RIG-N or MAVS to activate IFN-β promoters. HEK293T cells were transfected with an IFN-β promoter Luciferase reporter plasmid, Renilla luciferase reporter plasmid, or NSP8-Flag, along with a control plasmid or OTUB2-V5 for 24 h. Then Luciferase reporter activities were induced by transfection of RIG-I(N)-Myc or MAVS-Flag expressing vectors into HEK293T cells for another 24 h. Cell lysate samples were analyzed using WB IFN-β-Luc reporter activities are normalized to Renilla luciferase and shown as fold induction. C OTUB2-IN inhibits the ability of OTUB2 to regulate NSP8. D OTUB2 promotes viral replication by enhancing NSP8 expression. Vero cells were co-transfected with NSP8-Flag and OTUB2-Myc and then infected with SARS-CoV-2 XBB (MOI = 0.1). At 2 hpi, the medium was replaced with fresh medium. Cells and supernatants were collected at 48 hpi. Viral nucleocapsid (N) protein levels and the expression of NSP8 and OTUB2 were analyzed by WB. E, F Knockdown of OTUB2 reduced viral replication. OTUB2 was knocked down in Caco-2 cells, followed by infection with SARS-CoV-2 XBB at an MOI of 0.1. At 2 hpi, the medium was replaced with fresh medium. Cells and supernatants were collected at 48 hpi. Protein levels were analyzed by immunoblotting, and viral RNA levels in the supernatants were quantified by RT-qPCR. G, H The synergistic effect of OTUB2 and PLpro enhances NSP8 expression to promote viral replication. Vero cells were transfected with expression plasmids for NSP8-Flag, PLpro-Flag, and OTUB2-Myc, followed by infection with SARS-CoV-2 XBB (MOI = 0.1). The medium was replaced at 2 hpi, and cells and supernatants were collected at 48 hpi. Viral N protein levels and the expression of NSP8, PLpro, and OTUB2 were examined by WB (G). Viral N gene mRNA levels in the supernatants were measured by RT-qPCR (H). Data represent three independent experiments and are shown as mean ± SD (n = 3). Statistical significance was determined by one-way ANOVA: ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001. OTUB2 increases SARS-CoV-2 infectivity through stabilizing NSP8. A, B OTUB2 promotes NSP8 inhibition on RIG-N or MAVS to activate IFN-β promoters. HEK293T cells were transfected with an IFN-β promoter Luciferase reporter plasmid, Renilla luciferase reporter plasmid, or NSP8-Flag, along with a control plasmid or OTUB2-V5 for 24 h. Then Luciferase reporter activities were induced by transfection of RIG-I(N)-Myc or MAVS-Flag expressing vectors into HEK293T cells for another 24 h. Cell lysate samples were analyzed using WB IFN-β-Luc reporter activities are normalized to Renilla luciferase and shown as fold induction. C OTUB2-IN inhibits the ability of OTUB2 to regulate NSP8. D OTUB2 promotes viral replication by enhancing NSP8 expression. Vero cells were co-transfected with NSP8-Flag and OTUB2-Myc and then infected with SARS-CoV-2 XBB (MOI = 0.1). At 2 hpi, the medium was replaced with fresh medium. Cells and supernatants were collected at 48 hpi. Viral nucleocapsid (N) protein levels and the expression of NSP8 and OTUB2 were analyzed by WB. E, F Knockdown of OTUB2 reduced viral replication. OTUB2 was knocked down in Caco-2 cells, followed by infection with SARS-CoV-2 XBB at an MOI of 0.1. At 2 hpi, the medium was replaced with fresh medium. Cells and supernatants were collected at 48 hpi. Protein levels were analyzed by immunoblotting, and viral RNA levels in the supernatants were quantified by RT-qPCR. G, H The synergistic effect of OTUB2 and PLpro enhances NSP8 expression to promote viral replication. Vero cells were transfected with expression plasmids for NSP8-Flag, PLpro-Flag, and OTUB2-Myc, followed by infection with SARS-CoV-2 XBB (MOI = 0.1). The medium was replaced at 2 hpi, and cells and supernatants were collected at 48 hpi. Viral N protein levels and the expression of NSP8, PLpro, and OTUB2 were examined by WB (G). Viral N gene mRNA levels in the supernatants were measured by RT-qPCR (H). Data represent three independent experiments and are shown as mean ± SD (n = 3). Statistical significance was determined by one-way ANOVA: ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001. To investigate the role of OTUB2 in SARS-CoV-2 infection, the SARS-CoV-2 XBB variant were employed to establish infection experiments in a biosafety level 3 (BSL-3) laboratory. NSP8 increased SARS-CoV-2 infection (Fig. 7D, lane 3), and OTUB2 enhanced NSP8 protein levels, further promoting SARS-CoV-2 infection (Fig. 7D, lane 4). Consistently, RT-qPCR analysis revealed that co-expression of NSP8 and OTUB2 resulted in higher mRNA levels of the SARS-CoV-2 structural proteins N, M, and E in both the supernatant and cell lysates compared with NSP8 expression alone (Supplementary Fig. S3D and E). Conversely, OTUB2 knockdown in Caco-2 cells reduced viral replication and decreased NSP8 and PLpro expression (Fig. 7E and F). Together, these findings indicate that OTUB2 promotes SARS-CoV-2 replication. To further examine this, we treated the cells with an OTUB2 inhibitor. The results showed that OTUB2 inhibition abolished its ability to promote viral replication via NSP8 stabilization (Fig. 7G lanes 7–8). Consistently, viral N mRNA levels in the supernatant were reduced (Fig. 7H lanes 7–10), further supporting a role for OTUB2 in facilitating SARS-CoV-2 replication through NSP8 stabilization. OTUB2 inhibitor suppresses SARS-CoV-2 virulence in hamster We next investigated the effect of OTUB2 inhibitor on the virulence of SARS-CoV-2 in a hamster infection model. Golden hamsters were treated with OTUB2-IN at a dose of 15 mg/kg for five administrations and subsequently infected intranasally with SARS-CoV-2 at a dose of 105.5 TCID50/mL (Fig. 8A). Compared with solvent-treated control hamsters, the OTUB2-IN-treated hamsters exhibited reduced copy numbers of viral RNA (based on the N gene), in both lung and spleen tissues (Fig. 8B and C). In addition, the OTUB2-IN-treated hamsters did not exhibit apparent body weight loss during the course of infection (Fig. 8D). Histopathological analysis at 6 days post-infection (dpi) revealed that OTUB2-IN treatment significantly alleviated typical lung pathology observed in control animals, including alveolar collapse and pulmonary edema (Fig. 8E and F). These findings were consistent with reduced expression of inflammatory factors, including TNF-α and IL-1β, in lung and spleen (Fig. 8G–J), and support the conclusion that OTUB2-IN limits viral replication and alleviates disease progression in SARS-CoV-2 infected hamsters.Fig. 8OTUB2-IN inhibits the virulence of SARS-CoV-2 in the golden hamster model. A Golden hamsters were treated with OTUB2-IN at doses of 0 and 15 mg/kg for 5 times at the indicated time points, followed by infection with SARS-CoV-2 XBB virus at a dose of 105.5 TCID50/mL via intranasal administration. B, C SARS-CoV-2 RNA loads in golden hamster lungs and spleens were measured at 6 dpi by quantifying mRNA levels of the N gene. D The weight of golden hamsters was monitored throughout the experimental period. E Representative hematoxylin and eosin (H&E)-stained lung images from differently treated mice. Uninfected: Normal H&E staining; Uninfected + OTUB2-IN: Nearly normal; Infected: Extensive neutrophil and lymphocyte infiltration, focal necrosis, presenting with interstitial pneumonia changes; Infected + OTUB2-IN: Alveolar and bronchial structures nearly normal, with mild neutrophil and lymphocyte infiltration. Arrows indicate areas of inflammatory cell infiltration or regions of pathological changes. Scale bar: 100 μm. F Case scores based on H&E staining of lungs. G–J mRNA expression levels of inflammatory factors in lungs and spleens were analyzed by RT-qPCR. n = 6 for each group. Statistical significance was analyzed using two-sided unpaired t-tests and one-way ANOVA (∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001). OTUB2-IN inhibits the virulence of SARS-CoV-2 in the golden hamster model. A Golden hamsters were treated with OTUB2-IN at doses of 0 and 15 mg/kg for 5 times at the indicated time points, followed by infection with SARS-CoV-2 XBB virus at a dose of 105.5 TCID50/mL via intranasal administration. B, C SARS-CoV-2 RNA loads in golden hamster lungs and spleens were measured at 6 dpi by quantifying mRNA levels of the N gene. D The weight of golden hamsters was monitored throughout the experimental period. E Representative hematoxylin and eosin (H&E)-stained lung images from differently treated mice. Uninfected: Normal H&E staining; Uninfected + OTUB2-IN: Nearly normal; Infected: Extensive neutrophil and lymphocyte infiltration, focal necrosis, presenting with interstitial pneumonia changes; Infected + OTUB2-IN: Alveolar and bronchial structures nearly normal, with mild neutrophil and lymphocyte infiltration. Arrows indicate areas of inflammatory cell infiltration or regions of pathological changes. Scale bar: 100 μm. F Case scores based on H&E staining of lungs. G–J mRNA expression levels of inflammatory factors in lungs and spleens were analyzed by RT-qPCR. n = 6 for each group. Statistical significance was analyzed using two-sided unpaired t-tests and one-way ANOVA (∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001). Discussion Ubiquitination and deubiquitination are important regulators of virus–host interactions, shaping antiviral signaling and controlling the stability of viral proteins (Isaacson and Ploegh, 2009; Martin-Vicente et al., 2022). NSP8 is a core component of the viral replication-transcription complex and is essential for efficient viral RNA synthesis (Gao et al., 2020; Zhang et al., 2023; Zong et al., 2023). Previous studies have shown that NSP8 undergoes host-driven ubiquitination and ISGylation, which restrict its function (Fan et al., 2024; Hou et al., 2025). However, the host deubiquitination mechanism that counteracts these restrictive modifications has remained unclear. In this study, we identify OTUB2 as a host deubiquitinase that directly interacts with NSP8, removes its polyubiquitin chains, and stabilizes the protein (Fig. 2, Fig. 3). Here, we show that SARS-CoV-2 exploits the host deubiquitinase OTUB2 to directly remove polyubiquitin chains from NSP8, thereby maintaining NSP8 protein stability. These findings identify OTUB2 as a host factor that protects a core component of the viral replication machinery from host-mediated ubiquitin-dependent restriction. In addition to the direct effect of OTUB2 on NSP8, our data reveal a second layer of regulation involving PLpro. SARS-CoV-2 encodes the papain-like protease PLpro, an essential viral protease that also functions as a multifunctional deubiquitinase and deISGylase, thereby antagonizing host antiviral responses (Moustaqil et al., 2021; Wu et al., 2024b). Consistent with the shared catalytic features of PLpro and OTUB2 as deubiquitinases (Sivakumar and Stein, 2021). Our previous work showed that PLpro removes ISGylation from NSP8 (Hou et al., 2025). Here, we further demonstrate that PLpro can also directly remove polyubiquitin chains from NSP8 (Fig. 5). Importantly, PLpro itself undergoes ubiquitin-proteasome-mediated degradation, and this process is counteracted by OTUB2 through removal of polyubiquitin chains from PLpro (Fig. 4). Together, these findings support a dual-track mechanism in which OTUB2 stabilizes NSP8 both directly and indirectly by maintaining PLpro stability (Fig. 9). Future identification of the E3 ubiquitin ligases responsible for PLpro ubiquitination, as well as the signals regulating this process during infection, will further refine our understanding of this pathway.Fig. 9Schematic of the mechanism by which the deubiquitinase OTUB2 stabilizes NSP8 and PLpro. The schematic was created using BioRender. Schematic of the mechanism by which the deubiquitinase OTUB2 stabilizes NSP8 and PLpro. The schematic was created using BioRender. OTUB2 is increasingly recognized as a multifunctional host regulator. Previous studies have implicated OTUB2 in DNA damage repair and in the negative regulation of type I interferon production through deubiquitination of TRAF3. OTUB2 has also been shown to stabilize PD-L1 in tumor cells, thereby contributing to immune suppression (Kato et al., 2014; Ren et al., 2024; Wu et al., 2024a). Together, these observations suggest that OTUB2 has intrinsic immune-modulatory capacity and may represent a biologically plausible host factor for viral exploitation. In this context, our findings support a model in which SARS-CoV-2 engages OTUB2 to reinforce the stability of replication-associated viral proteins. More broadly, this suggests that SARS-CoV-2 not only evades host restrictive ubiquitination, but also co-opts host deubiquitination pathways to preserve its replication machinery. From a translational perspective, our findings also nominate OTUB2 as a potential target for host-directed antiviral intervention. The structural basis of OTUB2 has been well characterized (Nanao et al., 2004), and small-molecule inhibitors such as OTUB2-IN have been developed to inhibit its deubiquitinase activity (Ren et al., 2024). Using both cell-based and animal models, we show that pharmacological inhibition of OTUB2 reduces SARS-CoV-2 replication, providing proof-of-concept evidence that this pathway may be therapeutically exploitable (Fig. 7, Fig. 8). At the same time, the broader regulatory functions of OTUB2 in host cells warrant careful evaluation of the selectivity, safety, and host consequences of OTUB2 inhibition. In addition, further studies will be needed to define the dynamics of the OTUB2-PLpro-NSP8 axis under endogenous infection conditions, to map the relevant ubiquitin chain types and modification sites on NSP8 and PLpro, and to determine which linkages OTUB2 removes. Conclusions In summary, our study identifies OTUB2 as a host deubiquitinase that promotes SARS-CoV-2 replication by stabilizing PLpro and NSP8. PLpro also contributes to NSP8 stabilization, and the presence of both OTUB2 and PLpro produces a stronger stabilizing effect than either protein alone. These findings highlight the role of deubiquitinases in SARS-CoV-2 replication and suggest OTUB2 as a potential antiviral target. Materials and methods Plasmid construction The plasmids encoding SARS-CoV-2 proteins used in this study were provided by Professor Peihui Wang’s Laboratory at Shandong University, including S-GFP, N-HA, M-Flag, E-Flag, NSP1/2/3 N/5/8/9/12/14/15/16-Flag, NSP6/10-GFP, ORF3a-Flag, ORF6-Myc, ORF7a-Flag, ORF8-Flag and ORF9b-HA. NSP8-Myc was constructed from NSP8-Flag via site-directed mutagenesis and verified by full-length sequencing and alignment. The PLpro-Flag plasmid was synthesized by Sangon Biotech Co., Ltd. (Shanghai, China), and subcloned into the pCAG vector using XhoI and BglII as restriction sites. All the HA-/Flag-tagged deubiquitinases employed in this study were commercially purchased from Addgene (Watertown, MA, USA). The OTUB2-Myc plasmid was constructed by homologous recombination and inserted into the VR1012 vector with EcoRV as the restriction site. Both the enzymatically inactive mutants and truncation variants of OTUB2 were generated using OTUB2-Myc as the template. All oligonucleotide primers are listed in Supplementary Table S1. Ub-HA/Myc, RIG-I(N)-Myc, MAVS, IFN-β-Luc, NF-κB-Luc, and Renilla have been previously described (Gao et al., 2022). Cells and transfection HEK293T (CRL-11268, ATCC, Manassas, VA, USA), Caco2 (HTB-37, ATCC) and Vero (CRL-1586, ATCC), HEK293T-hACE2 (BEI Resources, Cat. No. NR-52511) cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; HyClone, South Logan, UT, USA) containing 10% heat-inactivated fetal bovine serum (04-001-1; Biological Industries, Kibbutz Beit Haemek, Israel) and 100 μg/mL penicillin-streptomycin. All cells were placed in a humidified atmosphere at 37 °C in an incubator containing 5% (vol/vol) CO2. DNA transfection into cell was carried out using Lipofectamine 2000 (Cat. No. 11668-019, Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. siRNA transfections were carried out by Lipofectamine RNAiMAX Reagent (13778150, Invitrogen). Reagents and antibodies Chemical reagents, including Vinblastine (Cat. No. S4504, Selleck, Houston, TX, USA), Bafilomycin A1 (Cat. No. S1413, Selleck), Bortezomib (Cat. No. S1013, Selleck) and MG132 (Cat. No. S2619, Selleck). CHX (Cat. No.66-81-9, Sigma-Aldrich, St. Louis, MO, USA), OTUB2 (Cat. No. HY-160768, MCE Shanghai, China), PLpro inhibitor (Cat. No. HY-17542, MCE). The following antibodies were used in this study: mouse anti-HA tag monoclonal antibody (Cat. No. MMS-101R, Biolegend, Peking, China); mouse anti-Myc tag monoclonal antibody (Cat. No. HY-P80232, MCE), mouse anti-Flag tag monoclonal antibody (Cat. No. F1804, Sigma), rabbit anti-Myc tag polyclonal antibody (Cat. No. 16286-1-AP, Proteintech, Wuhan, Hubei Province, China), rabbit anti-OTUB2 polyclonal antibody (Cat. No. 12066-1-AP, Proteintech), rabbit anti-NSP3/PLpro polyclonal antibody (Cat. No. GTX135796, GeneTex), rabbit anti-NSP8 monoclonal antibody (Cat. No. GTX636997, GeneTex), mouse anti-Actin monoclonal antibody (Cat. No. A00702-100, Genscript, Piscataway, New Jersey, USA), Alexa Fluor 488-conjugated secondary antibody (Cat. No. A11001, Invitrogen, Carlsbad, CA, USA), Alexa Fluor 568-conjugated secondary antibody (Cat. No. A11011, Invitrogen), horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG secondary antibody (Cat. No. 111-035-045, Jackson, West Grove, PA, USA) and HRP-conjugated goat anti-mouse IgG secondary antibody (Cat. No. 111-035-062, Jackson). All antibodies were used according to the manufacturer’s protocol. Immunoblot analysis For Western blot (WB) analysis of cell-associated proteins, expression plasmids were transfected into HEK293T, Caco-2, or Vero cells. At 48 h post-transfection, both cells and culture supernatants were collected and centrifuged at 10,000×g for 5 min. Cell pellets were lysed in buffer containing 50 mM Tris-HCl (pH 7.8), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 4 mM EDTA. Lysates and culture supernatants were mixed with 4 × loading buffer (0.08 M Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 0.1 M DTT, and 0.2% bromophenol blue), boiled at 100 °C for 30 min, and briefly vortexed to shear genomic DNA. Proteins were separated by SDS–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes (10401396; GE Whatman, Shanghai, China). Membranes were blocked and incubated with the indicated primary antibodies, followed by horseradish peroxidase–conjugated secondary antibodies. Signals were detected using the UltraSensitive ECL Chemiluminescence Detection Kit (B500024; Proteintech) and imaged using C500 Biosystems (Azure), and band intensities were quantified using ImageJ software. Co-immunoprecipitation HEK293T cells were transfected with the indicated plasmids according to the experimental design. To inhibit proteasomal degradation, cells were treated with 5 mM MG132 12 h prior to harvesting. After collection, cells were washed twice with ice-cold PBS and lysed in 1 mL of lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, supplemented with Complete Protease Inhibitor Cocktail (11836170001; Roche, Basel, Switzerland) at 4 °C for 1 h. Lysates were clarified by centrifuge at 12,000×g for 30 min at 4 °C. For Co-IP, Protein G-agarose beads (11243233001; Roche) were pre-incubated with anti-HA, anti-Myc, or anti-Flag antibodies for 1 h at 4 °C. The antibody-coupled beads were then added to the clarified lysates and incubated for 3 h or overnight at 4 °C with gentle rotation. After incubation, the beads were washed six times with cold wash buffer (20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 0.1 mM EDTA, 0.05% Tween-20), followed by brief centrifugation at 800×g for 1 min at 4 °C between washes. Bound proteins were eluted with 0.1 M glycine-HCl (pH 2.5), resolved by SDS-PAGE, and analyzed by immunoblotting. SARS-CoV-2 infectivity and detection For SARS-CoV-2 infection, cells were seeded in 12-well plates and cultured to approximately 70%–80% confluence. Prior to infection, cells were washed twice with phosphate-buffered saline (PBS) to remove residual serum. Subsequently, cells were incubated with the indicated SARS-CoV-2 XBB strains at a multiplicity of infection (MOI) of 0.01 in serum-free medium at 37 °C for 2 h. During this adsorption period, plates were gently agitated every 30 min to promote uniform viral attachment. After incubation, the inoculum was removed, and cells were washed once with PBS to eliminate unbound virus. Fresh culture medium supplemented with 2% fetal calf serum (FCS) was then added, and cells were maintained at 37 °C in a humidified incubator with 5% CO2 for the indicated time points before subsequent analysis. Protein expression in cells were analyzed by IB, while viral levels in the supernatant were measured by real-time quantitative PCR (RT-qPCR). RT-qPCR Total RNA was extracted using TRIzol reagent (15596-026; Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. First-strand cDNA was synthesized from 250 to 1000 ng of total RNA using the EasyScript First-Strand cDNA Synthesis SuperMix (AE301; TransGen Biotech, Beijing, China). Negative controls included reactions containing only H2O or lacking reverse transcriptase. Quantitative PCR was performed using FastStart Universal SYBR Green Master (Rox) (491314001; Roche, Basel, Switzerland). Gene expression levels were normalized to GAPDH, and relative transcript abundance was calculated using the comparative Ct (ΔΔCt) method. Primer sequences used in this study are listed in Supplementary Table S1. CRISPR-Cas9-mediated OTUB2 gene knockout OTUB2-knockout HEK293T cells were generated using the CRISPR/Cas9 system as described previously. The single guide RNA (sgRNA) targeting the OTUB2 gene (5′ -ACCGCCATCCGCAAGACCAATGG-3′; 5′-GATCACGGCGTTGTCGCAGGTGG-3′) was designed using the online software (CCTop, https://cctop.cos.uni-heidelberg.de) and cloned into the lentiCRISPR v2 vector. Lentiviral particles were produced by co-transfecting HEK293T cells with lentiCRISPRv2-OTUB2-sgRNA, pMD2.G (Addgene #12259), and psPAX2 (Addgene #12260). The viral supernatant was collected 48 h after transfection and used to infect HEK293T cells. At 48 h post-infection, cells were selected with puromycin (2 μg/mL). Single cells were subsequently seeded into 96-well plates by serial dilutions to isolate single cell colonies. These clones were expanded and screened for OTUB2 knockout by DNA sequencing and Western blotting analysis. Deubiquitination assay Cell-based deubiquitination assay: OTUB2/PLpro deubiquitinated NSP8. HEK293T cells were transfected with indicated plasmids and treated with 5 μM MG132 for 12 h prior to harvest. Co-IP (Co-IP with anti-Flag) and Western blot (WB) analyses were performed. In vitro deubiquitination assay with purified protein: ubiquitinated NSP8 was isolated from HEK293T cells co-transfected with Ub-HA and NSP8-Flag expression plasmids, followed by purification from cell lysates using anti-Flag antibody-conjugated Protein G agarose beads. OTUB2-Myc was transfected into HEK293T cells, and the protein was purified by Co-IP. Then, ubiquitinated NSP8 was incubated with purified OTUB2 in deubiquitination buffer (20 mM Tris-HCl, pH 8.0, 200 mM NaCl, 1 mM EDTA, 10 mM DTT, 5% glycerol) at 37 °C for 1 h. Reactions were analyzed by immunoblotting to assess the ubiquitination status of NSP8. Immunofluorescence assay (IFA) HeLa cells were plated onto glass-bottom culture dishes and transfected with the indicated plasmids. 24 hs post-transfection, cells were fixed with 4% paraformaldehyde for 10 min, followed by three washes with PBS. Cells were then permeabilized using 0.25% Triton X-100 at room temperature for 10 min, washed with PBS, and blocked with 5% bovine serum albumin for 1 h. Subsequently, cells were incubated with the indicated primary antibodies at room temperature for 2 h. After three washes with PBST (P3563; Sigma), cells were incubated with Alexa Fluor–conjugated secondary antibodies for 1 h. Nuclei were counterstained with DAPI (4′,6-diamidino-2-phenylindole; D9542; Sigma) for 5 min. Fluorescence images were acquired using a Nikon laser scanning confocal microscope provided by core facility of the first hospital of Jilin University. Hamsters and infection Syrian golden hamsters were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, Chian). All welfare and experimental procedures were carried out strictly in accordance with the Guide for the Care and Use of Laboratory Animals and the related ethical regulations. All efforts were made to minimize animal suffering. The golden hamsters (4–5 weeks old) were randomly divided into four groups, and each group contained six mice. One group was treated with the dosage of 15 mg/kg OTUB2-IN for five times every two days or one day via intraperitoneal injection, then infected with a mouse-adapted SARS-CoV-2 XBB at a dosage of 105.5 TCID50/mL via intranasal challenge. No OTUB2-IN treatment and SARS-CoV-2 infection were used as a negative control. Hematoxylin and eosin (H&E) Hamsters were euthanized under anesthesia, and lung tissues were harvested. Tissue samples were fixed in 4% paraformaldehyde for 48 h, dehydrated through graded ethanol, cleared in xylene, and embedded in paraffin. Paraffin blocks were sectioned at 3 μm, mounted onto glass slides, and baked at 60 °C. Sections were deparaffinized, rehydrated, and stained with hematoxylin, followed by eosin counterstaining. After dehydration and xylene clearing, sections were mounted with neutral resin. Histopathological changes were examined under a light microscope. Statistical analysis All data represent the results of three independent experiments and are presented as the mean ± standard deviation (SDs). Differences among groups were analyzed using ANOVA and t-test. ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗, P < 0.001; ∗∗∗∗, P < 0.0001. Data availability All data and reagents are available upon request. Ethics statement This study was approved by the Ethics Committee of the First Hospital of Jilin University (No. 2023-HS-034), and the procedures were carried out in accordance with approved guidelines. All research participants signed informed consent forms. All animal experiments were approved by the ethics committee of Changchun Institute of Biological Products Co., Ltd (CCIBP202511-02). Author contributions Wenying Gao: investigation, data curation, writing-original draft. Hongfei Wang: investigation. Jingguo Xin: data curation, methodology. Chenjia Gu: investigation. Lu Qiu: resources, conceptualization. Xue Zhang: software. Chunlei Wang: visualization. Qingxiang Zhang: methodology. Shuai Li: validation, resources. Guangquan Li: Writing-review & editing. Wenyan Zhang: funding acquisition, writing-review & editing. All authors have read and approved the final version of the manuscript. Conflict of interest The authors declare that there are no conflicts of interest.